Royal London Asset Management’s Teva Pharmaceuticals TEVA Stock Holding History

Royal London Asset Management’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.49M	Sell	43,972 -6,600	-13%	-$220K	﹤0.01%	590
2026 Q1	$1.52M	Sell	50,572 -5,600	-10%	-$180K	﹤0.01%	583
2025 Q4	$1.75M	Buy	56,172 +1,881	+3%	+$46.3K	﹤0.01%	581
2025 Q3	$1.1M	Hold	54,291	–	–	﹤0.01%	601
2025 Q2	$910K	Hold	54,291	–	–	﹤0.01%	644
2025 Q1	$834K	Buy	+54,291	New	+$970K	﹤0.01%	645

Other funds holding TEVA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

HIIFS

Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return

WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return

MIFH

Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

LIM

Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

Royal London Asset Management's TEVA Position: Q2 2026 in Review

Royal London Asset Management reduced its Teva Pharmaceuticals (TEVA) stake by 13% in Q2 2026, selling an estimated $220K and leaving 43,972 shares worth $1.49M. The position accounts for ﹤0.01% of the portfolio, ranked #590.

Royal London Asset Management first reported a position in TEVA in Q1 2025 and has held it in 6 quarters since. The position peaked at $1.75M in Q4 2025. 672 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

Royal London Asset Management held 43,972 shares of Teva Pharmaceuticals worth $1.49M as of Q2 2026.
Royal London Asset Management sold 6,600 Teva Pharmaceuticals shares in Q2 2026, an estimated $220K.
Teva Pharmaceuticals made up ﹤0.01% of Royal London Asset Management's portfolio in Q2 2026, its #590 holding.
Royal London Asset Management first reported a position in Teva Pharmaceuticals in Q1 2025 and has held it in 6 quarters since.
Royal London Asset Management's Teva Pharmaceuticals position peaked at $1.75M in Q4 2025.
672 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on Royal London Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.